Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Nivolumab in RM-HNSCC
NCT03655444Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended Phase 2 Dose at 3 months and Overall Survival at 13 months. Started May 2019; status: terminated.
02
Drugs
abemaciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03655444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655444.